Evidence map›Paper›PMID 40571751›Full record

SynthesisAesthetic plastic surgery2025

Utility of Tranexamic Acid in Reduction Mammaplasty: A Systematic Review and Meta-Analysis.

Ethan Fung, Keisha E Montalmant, Jacquelyn M Roth, Maxwell Godek, Jian H Li, Bernice Z Yu, Peter W Henderson

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Aesthetic plastic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ethan FungDivision of Plastic and Reconstructive Surgery, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1259, New York, NY, USA. ethanfungny@gmail.com.ORCID 0000-0002-6785-0865
Keisha E MontalmantDivision of Plastic and Reconstructive Surgery, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1259, New York, NY, USA.
Jacquelyn M RothDivision of Plastic and Reconstructive Surgery, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1259, New York, NY, USA.
Maxwell GodekDivision of Plastic and Reconstructive Surgery, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1259, New York, NY, USA.
Jian H LiSUNY Upstate Medical University, Norton College of Medicine, Syracuse, New York, USA.
Bernice Z YuDivision of Plastic and Reconstructive Surgery, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1259, New York, NY, USA.
Peter W HendersonDivision of Plastic and Reconstructive Surgery, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1259, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of tranexamic acid (TXA) in reduction mammaplasty is increasing among plastic surgeons. Its efficacy and impact on complications, however, are not yet well understood. This study aims to comprehensively evaluate the impact of TXA on postoperative outcomes in reduction mammoplasty.

methodsA systematic review was conducted according to PRISMA guidelines. Five databases were queried to identify studies reporting TXA application in breast surgery. A dual-screener approach was employed to select reduction mammaplasty studies for full-text screening. Primary outcomes assessed were hematoma and seroma; secondary outcomes assessed were surgical site infection (SSI), nipple-areola complex (NAC) necrosis, drain output, drain duration, and thromboembolic events. Data were pooled, and a meta-analysis was performed. Odds ratios (OR) and mean differences were reported via the Mantel-Haenszel and Inverse-Variance methods, respectively.

resultsSeven studies with a total of 1396 patients were included, with 53.1% of patients (n = 741) receiving TXA. Of those receiving TXA, 100% of patients received TXA intraoperatively, and 62.6% of patients (n = 464) received both topical and intravenous administration. TXA administration significantly reduced postoperative hematoma formation (OR 0.35; 95% CI [0.20-0.63]; P < 0.001), with 2.3% of patients (n = 17) developing hematomas in the TXA group, compared to 7.2% of patients (n = 47) in those who did not receive TXA. No statistically significant differences were found in seroma rates, SSI, NAC necrosis, or drain duration. No thromboembolic events were reported in either group.

conclusionTXA administration during reduction mammaplasty reduced the incidence of postoperative hematoma formation without increasing complications. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors   www.springer.com/00266 .

Indexed as

Antifibrinolytic AgentsBlood Loss, SurgicalMammaplastyTranexamic AcidFemaleHematomaHumansPostoperative ComplicationsRisk AssessmentSeromaTreatment OutcomeAntifibrinolytic AgentsTranexamic AcidBreast reductionHematomaReduction mammaplastySeromaTranexamic acid

Identifiers

PMID40571751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.